- Home
- FFWM vs AUTL Comparison
FFWM vs AUTL Comparison
Compare FFWM & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFWM | AUTL |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United Kingdom |
| Employees | 551 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.3M | 368.6M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FFWM | AUTL |
|---|---|---|
| Price | $6.40 | $1.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $6.17 | ★ $8.33 |
| AVG Volume (30 Days) | 699.2K | ★ 3.9M |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,621,000.00 | $51,128,000.00 |
| Revenue This Year | $166.48 | $658.11 |
| Revenue Next Year | $6.86 | $91.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 47.55 | ★ 406.67 |
| 52 Week Low | $4.42 | $1.11 |
| 52 Week High | $7.36 | $2.80 |
Technical Indicators
Market Signals| Indicator | FFWM | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 76.33 | 56.48 |
| Support Level | $6.00 | $1.46 |
| Resistance Level | $6.11 | $1.69 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 98.27 | 73.33 |
Price Performance
Historical ComparisonAbout FFWM First Foundation Inc.
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.